Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances

ABSTRACT Tardive dyskinesia (TD) may occur in never-medicated patients with psychotic illness, indicating the existence of non-medication, possibly disease-related, causes. We tested the

hypothesis that, independent of the antipsychotic-induced rise in prolactin, the incidence of TD would be associated with the incidence of prolactin-related sexual disturbances (PRSD), which

would be suggestive of a common pathology involving multiple dopamine tracts. Simple, global measures of TD and PRSD (loss of libido, amenorrhea, gynaecomastia, impotence, and galactorrhea)

were rated in a prospective, observational European Health Outcomes Study (SOHO). New onset of TD and new onset of PRSD at 3, 6, and 12 months was analyzed in a risk set of 4263 patients

using a Cox proportional hazard model yielding adjusted hazard ratios (aHR). Incidence of TD was significantly and linearly comorbid with the incidence of PRSD in both men and women.

Compared to those with no PRSD, the risk for TD was 2.0 (95% CI: 1.1, 3.7) with one PRSD, 2.4 (95% CI: 1.3, 4.5) with two PRSD, and 3.6 (95% CI: 1.1, 11.8) with three PRSD. Associations were

stronger in those who only had received prolactin-sparing medications (aHR per unit PRSD increase=2.0, 95% CI: 1.2, 3.3) than in those who only had received prolactin-raising medications

(aHR=1.3, 95% CI: 0.9, 1.9). In people with schizophrenia, TD and PRSD show comorbidities that are independent of antipsychotic-induced alterations in plasma prolactin. This may suggest a

shared, pandopaminergic pathological mechanism associated with schizophrenia itself, rather than only a medication effect. SIMILAR CONTENT BEING VIEWED BY OTHERS HYPERPROLACTINEMIA AND MALE

SEXUAL FUNCTION: FOCUS ON ERECTILE DYSFUNCTION AND SEXUAL DESIRE Article 20 June 2023 SEX DIFFERENCES IN AUTONOMIC ADVERSE EFFECTS RELATED TO ANTIPSYCHOTIC TREATMENT AND ASSOCIATED HORMONE

PROFILES Article Open access 06 January 2024 UNDERSTANDING THE DOPAMINERGIC PATHWAY RELATIVE TO MEN’S SEXUAL DYSFUNCTION IN PATIENTS WITH PARKINSON’S DISEASE: A NARRATIVE REVIEW WITH

IMPLICATIONS FOR FUTURE RESEARCH Article 26 December 2022 INTRODUCTION Only a minority of patients with a diagnosis of schizophrenia develop tardive dyskinesia (TD) over the course of

antipsychotic treatment, indicating that some individuals carry a particular vulnerability to this condition. Although treatment-emergent TD has been reported in patients taking

antipsychotic medications, the condition also occurs in patients not exposed to antipsychotic medication (Fenton et al, 1994). Therefore, some of the causes contributing to the risk of TD

are thought to be intrinsic to the disease itself, possibly in interaction with age-related changes in the dopamine system (van Os et al, 1997). Although the nigrostriatal pathway is central

in theories on the causes of TD, any hypothesized pathophysiological mechanisms may well extend to other dopamine tracts. If this were true, the rate of TD should be associated with

indicators of dysfunction of other dopamine tracts, suggesting that TD is only one indicator of a much more widespread, pandopaminergic dysfunctional state. The tubero-infundibular dopamine

pathway regulates, by inhibition, pituitary prolactin secretion, causing sexual adverse events such as loss of libido, amenorrhea, gynaecomastia, impotence, and galactorrhea (Haddad and

Wieck, 2004; Halbreich et al, 2003; Knegtering et al, 2003). There is some evidence that TD is associated with a deviant neuroendocrine response following prolactin challenge (Csernansky et

al, 1986; Monteleone et al, 1988). However, not all the evidence is conclusive. Some authors reported differential prolactin responses in women but not in men, (Glazer et al, 1981), whereas

others found no dissimilarities in prolactin response between patients with and without TD (Asnis et al, 1979; Jeste et al, 1981; Tripodianakis et al, 1983). As the above experimental

studies may be sampling around small effect sizes producing inconsistent results, a complementary epidemiological approach, focusing on prospective associations between evidence of

abnormalities of the tubero-infundibular pathway and onset of TD in large samples, may be productive. While it is difficult to obtain plasma prolactin in large epidemiological studies,

sexual disturbance may serve as an indirect measure. Although the sexual disturbances seen in schizophrenia are of multifactorial origin, and therefore only in part attributable to

illness-related or medication-related prolactin levels (Haddad and Wieck, 2004; Halbreich et al, 2003; Knegtering et al, 2003), they may nevertheless serve as an indirect measure for

prolactin elevation in epidemiological studies, in particular if numerous confounding variables can be adequately controlled for. In the current paper prospective data from a large cohort of

patients treated in routine clinical settings was used to examine the incident comorbidities of prolactin-related sexual disturbances (PRSD) and TD, applying analytical methods for complete

adjustment of multiple confounding factors. As any association between PRSD and TD may be caused by their joint dependency on antipsychotic medication, analyses were stratified depending on

whether the prescribed antipsychotic was prolactin-sparing or prolactin-raising. We hypothesized that if the association between PRSD and TD were medication-induced, this should be more

apparent in the group exposed to prolactin-raising medications and higher levels of PRSD. If, however, observed comorbidity between PRSD and TD were intrinsic to the psychotic illness

itself, associations should be equally or more evident in the group prescribed prolactin-sparing medications with lower levels of PRSD. METHODS DESIGN AND PATIENTS The SOHO study is an

ongoing, 3-year prospective, observational health outcome study of the treatment of schizophrenia in Europe. Data was collected using a data collection form with a selection of measures that

considered simplicity and ease of use with no training requirement. Investigators assessed the TD and PRSD that they judged to be associated with antipsychotic drug treatment. The basis for

both ratings was clinical judgement. TD was rated on a four-point scale: (1) not present, (2) present, but does not significantly interfere with patient's functioning or health–related

quality of life, (3) present, and significantly interferes with patient's functioning or health–related quality of life, (4) present, and outweighs therapeutic effect. Full details of

the SOHO study design have been published previously (Haro et al, 2003). Ethics Committee approval and informed consent was obtained as required by national regulations. PRSD AND VALIDATION

OF ASSOCIATION WITH PROLACTIN Loss of libido, amenorrhea or other menstrual disturbance, gynaecomastia, galactorrhea, and impotence or sexual dysfunction were rated on the basis of clinical

judgment on a three point scale: (1) not present, (2) present, (3) not applicable. In order to validate their hypothesized association with prolactin, a variable was constructed dividing

patients into two groups: those prescribed prolactin-raising medications (all first-generation oral and depot antipsychotics [FGA], risperidone, and amisulpiride) after each of the four

visits over the 12-month period, and patients prescribed prolactin-sparing medications (all second-generation antipsychotics [SGA] except risperidone and amisulpiride) after each of the four

visits over the 12-month period (Haddad and Wieck, 2004; Knegtering et al, 2003). Associations between PRSD and the variable reflecting prolactin-raising or prolactin-sparing group

(hereafter: antipsychotic-induced prolactin) were examined in order to test whether PRSD would be higher in those exposed to prolactin-raising medication. ANTIPSYCHOTIC MEDICATION AND THE

ASSOCIATION BETWEEN PRSD AND TD As any association between PRSD and TD may be caused by their joint dependency on antipsychotic medication as explained earlier, associations between PRSD and

TD were examined for moderation by type of medication, again using the ‘antipsychotic-induced prolactin’ variable reflecting prescription of prolactin-sparing or prolactin-raising

antipsychotics. DATA ANALYSIS Each individual had four observations: baseline, 3, 6, and 12-month follow-up. For the purpose of the analyses, TD and PRSD were treated as dichotomous outcomes

as follows: TD: present=score 2, 3 or 4 _vs_ not present=score 1; PRSD: present=score 2 _vs_ not present=score 1 and 3. The ‘not applicable’ ratings for the PRSD were recoded ‘not present’

because the majority of subjects with a rating of ‘not applicable’ had been taking medication and therefore were per definition at risk of developing PRSD. The only item truly considered

‘not applicable’ was amenorrhea in men. PRSD was also expressed as a sum score indicating the number of PRSD (0, 1, 2, 3 or more). In order to calculate the incidence rates of TD and PRSD,

three time bands were constructed (baseline—3 months, 3–6 months, and 6–12 months). Each person was allocated person-time according to the interval from baseline to the visit in which a

patient was diagnosed with TD or, if no such diagnosis was made, to the last visit. Incidence rates for each time band were calculated by dividing the number of incident cases by the total

person-years. The cumulative incidence of TD or PRSD was calculated by dividing the total number of incident cases of TD or PRSD by the total person-years. In order to assess the degree of

comorbidity between TD and PRSD, associations between 12-month incidence of TD and 12-month incidence of PRSD were calculated in a risk set free of TD and PRSD at baseline, using a Cox

proportional hazard survival regression model of survival time without TD with PRSD as a time-varying covariate. ADJUSTMENT BY PROPENSITY SCORE Covariates were those agreed upon by the SOHO

advisory board and included sex, age, age of first contact, body mass index, first episode status, compliance, and country among others (full list of covariates available on request). In

addition, guided by previous literature, the following time-varying variables measured at the time of TD and PRSD assessments at 3, 6, and 12 months were included (Caligiuri et al, 1997;

Correll et al, 2004; Halbreich et al, 2003; Lieberman et al, 1994; van Os et al, 2000; Yuen et al, 1996): treatment with SGA or FGA (pre- and post-assessment occasion), Clinical Global

Impression positive, negative, cognitive, and depressive symptoms, other medications such as antidepressants, anticholinergics, and mood stabilizers. Approximately 80% of the sample was

included in the model with all covariates, due to missing values in the covariates. As there were many confounding variables included in the models, traditional control for confounding by

inclusion of covariates in the model may not be sufficient, as the degree of ‘control’ afforded by such models depends on the overlap in characteristics between the two outcome groups. The

use of the propensity score has been suggested as a means to obtain more complete control (Joffe and Rosenbaum, 1999; Rubin, 1997) in these circumstances. A ‘propensity score’ is a

model-based predicted probability of being exposed (in this case, of being in the group with sexual side effects). Predictors in the model are all of the potential confounding variables (ie

characteristics on which the groups differ). Instead of controlling for a long list of confounders, the propensity score itself is controlled for, thus effectively controlling for _all_ of

the covariates included in the propensity models, and minimizing the loss of degrees of freedom in controlling for confounders. Associations between PRSD and TD were expressed as incidence

rate ratios and Cox proportional hazard ratios (unadjusted: HR; adjusted: aHR), together with their 95% confidence intervals. Interactions with sex and the antipsychotic-induced prolactin

variable were assessed by Wald test (Clayton and Hills, 1993). Reported probability values for the predictor variable reflect two-sided tests of the null hypothesis of no association. All

analyses were performed using the computer package STATA, version 9.1 (StataCorp., 2005). RESULTS BASELINE CHARACTERISTICS A total of 9645 patients had non-missing data for PRSD and TD at

baseline. The prevalence of TD in these 9645 was 898 (9.3%), and the prevalence of any PRSD was 5139 (53.3%); loss of libido: 45.6%; impotence or sexual dysfunction: 33.5%, gynaecomastia:

3.1%, galactorrhea 2.0%; amenorrhea in women: 25.6%. The risk set of patients without TD and without PRSD at baseline consisted of 4263 individuals. The mean age of these 4263 was 38.8 years

(SD=13.5), 58.9% were men, 16.4% were first episode and 34.4% had been exposed to an SGA in the 6 months before enrolment. After the baseline assessment, the proportion exposed to SGA rose

to 85.0%. The number of individuals in the risk set prescribed prolactin-raising medication at all visits post-baseline was 1216 (40%), and the number prescribed prolactin-sparing

medications at all visits post-baseline was 1812 (60%). PRSD AND VALIDATION OF ASSOCIATION WITH PROLACTIN Over the follow-up period, there were 1162 incident cases of PRSD (loss of libido:

936; impotence or sexual dysfunction: 612; gynaecomastia: 60; galactorrhea: 41; amenorrhea in women: 198). Of the 1162 patients presenting with incident PRSD, 784 had one, 519 had two, and

68 had three PRSD. The incidence of PRSD was 37.0% (95% CI: 34.9, 39.2), and higher in the group prescribed only prolactin-raising medications (43%, 95% CI: 39–48) than in the group

prescribed only prolactin-sparing medications (32%, 95% CI: 29–35; _P_<0.001). INCIDENCE OF TD Over the follow-up period, there were 95 incident cases of TD, yielding a TD incidence rate

of 2.6% (95% CI: 2.1, 3.2). The TD incidence was significantly comorbid with PRSD, independent of a range of confounders (Table 1). The sum score of incident PRSD and TD were associated with

each other in a dose–response fashion: compared to those with no PRSD (HR=1), those with 1 PRSD (aHR=2.0, 95% CI: 1.1, 3.7, _P_=0.024), 2 PRSD (aHR=2.4, 95% CI: 1.3, 4.5, _P_=0.008), and 3

PRSD (aHR=3.6, 95% CI: 1.1, 11.8, _P_=0.036) were at progressively higher risk of developing TD (summary aHR linear trend: 1.6, 95% CI: 1.2, 2.0, _P_=0.001). There were no interactions with

sex (any PRSD excluding amenorrhea: _χ_2=2.59, _P_=0.11). INCIDENCE OF TD AND ANTIPSYCHOTIC-INDUCED PROLACTIN All the effect sizes of the association between PRSD and TD were larger in the

group of individuals prescribed only prolactin-sparing medications, although formal comparisons between the two effects sizes remained statistically inconclusive by conventional alpha (Table

2). DISCUSSION A significant association was found between TD and sexual disturbances in patients with schizophrenia: the minority of individuals, who were at risk of developing TD, also

displayed an elevated risk of developing PRSD. In interpreting the results, it was assumed that loss of libido, impotence or sexual dysfunction, gynaecomastia, galactorrhea, and amenorrhea

in women were prolactin-related to at least a degree. This, however, may be questioned, as many factors apart from prolactin may impact on these variables. For example, dopamine itself plays

a role in general arousal (Paredes and Agmo, 2004) and antipsychotic-induced histaminergic, noradrenergic, alpha–blocking, and anticholinergic effects, as well as the effects of concomitant

medication, all potentially influence sexual behaviour (Knegtering et al, 2003). Nevertheless, the validity of our exposure, in terms of it reflecting prolactin activity, is supported by

(i) the simple and basic observation that patients reporting sexual dysfunctions on average have higher serum prolactin levels (Knegtering et al, 1999), and (ii) the fact that the current

analyses did indeed confirm that PRSD were more common among those prescribed prolactin-raising medications. Furthermore, treatment-emergent sexual adverse events have been reported during

treatment with antipsychotics known to elevate prolactin levels relatively specifically, suggesting prolactin may be related to the incidence of sexual dysfunction with a relatively small

additional role suggested for histaminergic, noradrenergic, serotonergic, and cholinergic mechanisms (Knegtering et al, 2003). In addition, gynaecomastia, galactorrhea, and amenorrhea are

among the clinical presentations more specifically associated with hyperprolactinaemia (Haddad and Wieck, 2004; Luciano, 1999). Assuming that all PRSD variables are prolactin-related to a

degree, arguably the simplest explanatory factor that can be evoked is that both PRSD and TD are caused by prolactin elevation induced by antipsychotic medications (Haddad and Wieck, 2004;

Knegtering et al, 2003). However, this is unlikely as the association between TD and PRSD was, if anything, stronger rather than weaker for prolactin-sparing medications with a lower risk

for both PRSD (Haddad and Wieck, 2004; Knegtering et al, 2003) and TD (Correll et al, 2004). Therefore, although antipsychotic medication may well contribute separately to the onset of both

TD and PRSD, the fact that survival without TD was at best only weakly associated with newly arising PRSD in those exposed to prolactin-raising medications suggests that the rise in

prolactin, occasioned by antipsychotic medications, is not the common mechanism causing TD and PRSD to cluster over time. This is not unexpected, given the fact that the rise in prolactin is

related to interactions between antipsychotic medication and D2 receptors that are outside the blood–brain barrier (Kapur et al, 2002; Knegtering et al, 2005), whereas the onset of TD is

likely to reflect the central effects of antipsychotic medication. In other words, prolactin-raising medications may contribute separately to the risk of both TD and PRSD in the long term,

but if the mechanisms and ‘incubation’ periods for these two outcomes are different, they will not be associated in time-to-event analyses as presented here. In contrast, their simultaneous

clustering over time in those exposed to prolactin-sparing medications suggests an underlying common and central vulnerability, involving more than one central dopamine tract, that may be

intrinsic to schizophrenia itself, and only detectable in the absence of external agents causing substantial increases in plasma prolactin that overshadow this internal, illness-related,

association. Indeed, a recent investigation reported pituitary enlargement in never-medicated patients with schizophrenia, compatible with the hypothesis of a central, illness-related,

mechanism (Pariante et al, 2005). Similarly, a recent report found high prolactin levels in a paranoid subgroup of never-medicated psychotic patients, suggestive of the existence of subtypes

of psychotic illness associated with differences in dopaminergic tone (Segal et al, 2004). Another possible explanation may reside in differential D2 sensitivity in groups with and without

TD (Shim et al, 2005). However, none of the above research findings provides a direct explanation for the association between PRSD and TD. Two basic, non-exclusive, types of explanations are

possible. The first is that the same cause contributes to the onset of two conditions with different underlying pathologies. For example, stress is the most prevalent systemic condition

associated with hyperprolactinaemia (Halbreich et al, 2003), and may be associated with TD through a mechanism involving raised cortisol levels (Aleem et al, 1988) or a mechanism involving

modulation of the dopamine receptor by estrogen and its diverse and complex influences on prolactin levels (Halbreich et al, 2003; Turrone et al, 2000). The second explanation is that the

same underlying pathology can be expressed pleiotropically as both TD and sexual disturbances, as both have been observed to be more prevalent in unmedicated patients with schizophrenia

(Aizenberg et al, 1995; Fenton et al, 1994; Gregory, 1957), possibly indicative of a pandopaminergic dysfunction related to schizophrenia itself. Although it is not possible to distinguish

between the two models on the basis of the current data, the latter explanation is the most parsimonious. The results should be interpreted in the light of several methodological

limitations. Our data derives from an observational study in which the investigator ‘observes and evaluates results of ongoing medical care without ‘controlling’ the therapy beyond normal

medical practice.’ Controlling the therapy beyond normal medical practice also applies to the measures used to evaluate the pathology of interest or invasive procedures like blood monitoring

(CPMP, 1996). By implication, this means that the current study relied on PRSD as a derived measure for prolactin. Many underlying causes may contribute to hyperprolactinaemia such as, for

example, systemic conditions (eg cirrhosis, chronic renal failure or meningiomas) and non-psychotropic medications acting on the CNS (eg verapamil, estrogens, and other substances (Halbreich

et al, 2003). However, the prevalences of these alternative causes are probably very low in our sample, and unlikely to have affected the current analysis in a non-random way. Similarly,

sexual functioning is influenced by many factors other than hyperprolactinaemia such as demographic factors (Nazareth et al, 2003) and chronic medical conditions like hypertension and

diabetes (Guay et al, 1999). Therefore, it is possible that, instead of prolactin, some of these other complex and interacting factors actually drive variation of sexual functioning and are

associated with the incidence of TD, in spite of the extensive list of covariates used in the analyses. REFERENCES * Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A (1995). Sexual

dysfunction in male schizophrenic patients. _J Clin Psychiatry_ 56: 137–141. CAS  PubMed  Google Scholar  * Aleem A, Kulkarni A, Yeragani VK (1988). Dexamethasone suppression test,

schizophrenia and movement disorder. _Acta Psychiatr Scand_ 78: 689–694. Article  CAS  Google Scholar  * Asnis GM, Sachar EJ, Langer G, Halpern FS, Fink M (1979). Normal prolactin responses

in tardive dyskinesia. _Psychopharmacology (Berlin)_ 66: 247–250. Article  CAS  Google Scholar  * Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV (1997). Incidence and risk factors

for severe tardive dyskinesia in older patients. _Br J Psychiatry_ 171: 148–153. Article  CAS  Google Scholar  * Clayton D, Hills M (1993). _Statistical Models in Epidemiology_. Oxford

Science Publications: Oxford. Google Scholar  * Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review

of 1-year studies. _Am J Psychiatry_ 161: 414–425. Article  Google Scholar  * CPMP (1996). _ICH Topic E 6 Guideline for Good Clinical Practice_. EMEA: London, UK. * Csernansky JG, Prosser E,

Kaplan J, Mahler E, Berger PA, Hollister LE (1986). Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. _Biol Psychiatry_

21: 632–642. Article  CAS  Google Scholar  * Fenton WS, Wyatt RJ, McGlashan TH (1994). Risk factors for spontaneous dyskinesia in schizophrenia. _Arch Gen Psychiatry_ 51: 643–650. Article 

CAS  Google Scholar  * Glazer WM, Moore DC, Bowers Jr MD, Brown WA (1981). Serum prolactin and tardive dyskinesia. _Am J Psychiatry_ 138: 1493–1496. Article  CAS  Google Scholar  * Gregory

BA (1957). The menstrual cycle and its disorders in psychiatric patients. I. Review of the literature. _J Psychosom Res_ 2: 61–79. Article  CAS  Google Scholar  * Guay MFA, Velasquez ME,

Perez MJ (1999). Characterization of patients in a medical endocrine-based center for male sexual dysfunction. _Endocr Pract_ 5: 314–321. Article  CAS  Google Scholar  * Haddad PM, Wieck A

(2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. _Drugs_ 64: 2291–2314. Article  CAS  Google Scholar  * Halbreich U, Kinon BJ, Gilmore JA,

Kahn LS (2003). Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. _Psychoneuroendocrinology_ 28(Suppl 1): 53–67. Article  CAS  Google Scholar

  * Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ _et al_ (2003). The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. _Acta

Psychiatr Scand_ 107: 222–232. Article  CAS  Google Scholar  * Jeste DV, Neckers LM, Wagner RL, Wise CD, Staub RA, Rogol A _et al_ (1981). Lymphocyte monoamine oxidase and plasma prolactin

and growth hormone in tardive dyskinesia. _J Clin Psychiatry_ 42: 75–77. CAS  PubMed  Google Scholar  * Joffe MM, Rosenbaum PR (1999). Invited commentary: propensity scores. _Am J Epidemiol_

150: 327–333. Article  CAS  Google Scholar  * Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002). The differential effects of atypical antipsychotics on prolactin

elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. _J Pharmacol Exp Therap_ 302: 1129–1134. Article  CAS  Google Scholar  * Knegtering

H, Blijd C, Boks MPM (1999). Sexual dysfunctions and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. _Schizophr Res_ 36: 355–356. Google Scholar  *

Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ (2003). What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

_Psychoneuroendocrinology_ 28(Suppl 2): 109–123. Article  CAS  Google Scholar  * Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ (2005). Predominant role of

the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. _Am J Psychiatry_ 162: 1010–1012. Article  Google Scholar  * Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J,

Woerner M, Novacenko H _et al_ (1994). Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. _Neuropsychopharmacology_ 11: 107–118.

Article  CAS  Google Scholar  * Luciano AA (1999). Clinical presentation of hyperprolactinemia. _J Reprod Med_ 44: 1085–1090. CAS  PubMed  Google Scholar  * Monteleone P, Maj M, Ariano MG,

Iovino M, Fiorenza L, Steardo L (1988). Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. _Psychopharmacology (Berlin)_ 96: 223–226. Article  CAS

  Google Scholar  * Nazareth I, Boynton P, King M (2003). Problems with sexual function in people attending London general practitioners: cross sectional study. _BMJ_ 327: 423. Article 

Google Scholar  * Paredes RG, Agmo A (2004). Has dopamine a physiological role in the control of sexual behavior? A critical review of the evidence. _Prog Neurobiol_ 73: 179–226. Article 

CAS  Google Scholar  * Pariante CM, Dazzan P, Danese A, Morgan KD, Brudaglio F, Morgan C _et al_ (2005). Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients

of the AEsop First-Onset Psychosis Study. _Neuropsychopharmacology_ 30: 1923–1931. Article  CAS  Google Scholar  * Rubin DB (1997). Estimating causal effects from large data sets using

propensity scores. _Ann Intern Med_ 127: 757–763. Article  CAS  Google Scholar  * Segal M, Avital A, Rojas M, Hausvater N, Sandbank S, Liba D _et al_ (2004). Serum prolactin levels in

unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. _Psychiatry Res_ 127: 227–235. Article  CAS  Google Scholar  * Shim JC, Kim

YH, Kelly DL, Lee JG, Conley RR (2005). Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. _J Neuropsychiatry Clin Neurosci_ 17: 221–226.

Article  CAS  Google Scholar  * StataCorp. (2005). _STATA Statistical Software: Release 9.0_. College Station: Texas. * Tripodianakis J, Markianos M, Garelis E (1983). Neurochemical studies

on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin. _Biol Psychiatry_ 18: 337–345. CAS  PubMed  Google Scholar  * Turrone P, Seeman MV, Silvestri S (2000). Estrogen

receptor activation and tardive dyskinesia. _Can J Psychiatry_ 45: 288–290. Article  CAS  Google Scholar  * van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997). Tardive dyskinesia:

who is at risk? _Acta Psychiatr Scand_ 96: 206–216. Article  CAS  Google Scholar  * van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG (2000). Changes in negative symptoms and the

risk of tardive dyskinesia: a longitudinal study. UK700 Group. _Acta Psychiatrica Scand_ 101: 300–306. Article  CAS  Google Scholar  * Yuen O, Caligiuri MP, Williams R, Dickson RA (1996).

Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. _Br J Psychiatry_ 168: 702–708. Article  CAS  Google Scholar  Download references

ACKNOWLEDGEMENTS The SOHO study has the financial support of Eli Lilly and Company Limited. DE Tenback was formerly employed by Eli Lilly and Company. The study was an initiative of Eli

Lilly, and designed with the help of an international panel of experts in the area of psychosis. Although Eli Lilly did have input into the design and conduct of the study, it did not have

any input in the analysis or reporting of the current analyses. The authors had unlimited access to the data. The views expressed are the authors' own. We thank the SOHO study group for

their contributions. _The SOHO Study Group_: Jean-Pierre Lepine, Hôpital Fernand Widal, Paris, France; Martin Knapp, LSE Health and Social Care, London School of Economics, Centre for the

Economics of Mental Health, Institute of Psychiatry, London, UK; Isabelle Gasquet, Hopital Paul Brousse, Villejuif, France; Jordi Alonso, Health Services Research Unit, Institut Municipal

d'Investigacio Medica, University of Barcelona, Barcelona, Spain; Josep Maria Haro, Research and Development Unit, Sant Joan de Déu-SSM, St Boi, Barcelona, Spain; Cees J Slooff,

Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands. _Disclosure of competing interest_: Diederik Tenback is a member of the Dutch advisory board for

Lilly and Bristol-Myers Squibb (BMS) and a former employee of Eli Lilly and Company (Lilly). He received research support from Lilly. Peter van Harten is a speaker for Lilly, Pfizer Inc

(Pfizer), AstraZeneca and Janssen-Cilag. Cees Slooff is a speaker or member of the Dutch advisory board for Lilly and BMS. Jim van Os is a speaker or member of the advisory board for Lilly,

BMS, Janssen-Cilag and AstraZeneca. He received grant or research support from Lilly, GSK, BMS and AstraZeneca. Jean-Pierre Lepine is a speaker or member of the advisory board for Lilly,

GlaxoSmithKline Inc. (GSK), Pfizer, Pierre Fabre Laboratories and Wyeth. He received grant or research support from Lilly, GSK and Pfizer. Martin Knapp has no financial interests to

disclose. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Psychiatric Center Altrecht, Den Dolder, The Netherlands Diederik E Tenback * Psychiatric Center Symfora Group, Amersfoort, The

Netherlands Peter N van Harten * Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands Cees J Slooff * Department of Psychiatry and Neuropsychology, South

Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands Jim van Os * Division of Psychological Medicine, Institute of Psychiatry,

London, UK Jim van Os Authors * Diederik E Tenback View author publications You can also search for this author inPubMed Google Scholar * Peter N van Harten View author publications You can

also search for this author inPubMed Google Scholar * Cees J Slooff View author publications You can also search for this author inPubMed Google Scholar * Jim van Os View author publications

You can also search for this author inPubMed Google Scholar CONSORTIA THE SOHO STUDY GROUP CORRESPONDING AUTHOR Correspondence to Jim van Os. RIGHTS AND PERMISSIONS Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Tenback, D., van Harten, P., Slooff, C. _et al._ Tardive Dyskinesia in Schizophrenia is Associated with Prolactin-Related Sexual Disturbances.

_Neuropsychopharmacol_ 31, 1832–1837 (2006). https://doi.org/10.1038/sj.npp.1301044 Download citation * Received: 08 July 2005 * Revised: 14 November 2005 * Accepted: 21 December 2005 *

Published: 15 February 2006 * Issue Date: August 2006 * DOI: https://doi.org/10.1038/sj.npp.1301044 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

KEYWORDS * tardive dyskinesia * prolactin * adverse events * dopamine * schizophrenia * tubero-infundibular